Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
Publication/Presentation Date
1-1-2005
Abstract
We sought to determine the benefits of stent implantation and abciximab in patients with diabetes mellitus and acute myocardial infarction (AMI) who underwent primary angioplasty. In a 2-by-2 factorial design, 2,082 patients with AMI were randomly assigned to balloon angioplasty versus stenting, with or without abciximab. Diabetes was present in 346 patients (16.6%). The primary end point was the composite incidence of death, disabling stroke, reinfarction, and ischemic target vessel revascularization (TVR). The primary end point at 1 year occurred significantly more frequently in diabetic than nondiabetic patients (21.9% vs 16.8%, p
Volume
95
Issue
1
First Page
1
Last Page
7
ISSN
0002-9149
Published In/Presented At
Stuckey, T. D., Stone, G. W., Cox, D. A., Tcheng, J. E., Garcia, E., Carroll, J., Guagliumi, G., Rutherford, B. D., Griffin, J. J., Turco, M., Lansky, A. J., Mehran, R., Fahy, M., Brodie, B. R., Grines, C. L., & CADILLAC investigators (2005). Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). The American journal of cardiology, 95(1), 1–7. https://doi.org/10.1016/j.amjcard.2004.08.054
Disciplines
Medicine and Health Sciences
PubMedID
15619385
Department(s)
Department of Medicine
Document Type
Article